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A Nonsense Mutation in the Human Homolog
of Drosophila rogdi Causes Kohlschutter–Tonz Syndrome
Adi Mory,1,2 Efrat Dagan,2,3 Barbara Illi,4 Philippe Duquesnoy,5 Shikma Mordechai,2 Ishai Shahor,6
Sveva Romani,4 Nivin Hawash-Moustafa,2 Hanna Mandel,1,6 Enza M. Valente,4 Serge Amselem,5
and Ruth Gershoni-Baruch1,2,*
Kohlschutter–Tonz syndrome (KTS) is a rare autosomal-recessive disorder of childhood onset, and it is characterized by global develop-
mental delay, spasticity, epilepsy, and amelogenesis imperfecta. In 12 KTS-affected individuals from a Druze village in northern Israel,
homozygosity mapping localized the gene linked to the disease to a 586,513 bp region (with a LOD score of 6.4) in chromosomal region
16p13.3. Sequencing of genes (from genomic DNA of an affected individual) in the linked region revealed chr16: 4,848,632 G>A, which
corresponds to ROGDI c.469C>T (p.Arg157*). The nonsensemutation was homozygous in all affected individuals, heterozygous in 10 of
100 unaffected individuals from the same Druze community, and absent from Druze controls from elsewhere. Wild-type ROGDI local-
izes to the nuclear envelope; ROGDI was not detectable in cells of affected individuals. All affected individuals suffered seizures, were
unable to speak, and had amelogenesis imperfecta. However, age of onset and the severity of mental and motor handicaps and that
of convulsions varied among affected individuals homozygous for the same nonsense allele.Kohlschutter–Tonz syndrome (KTS) (MIM 226750) is
described as a rare autosomal-recessive neurodegenerative
disorder characterized by progressive dementia, spasticity,
and epilepsy.1,2 A clinical marker of KTS is a generalized
enamel defect, amelogenesis imperfecta, which is most
obvious as yellowed teeth. KTS was first identified in fami-
lies from Switzerland,1,2 Sicily,3 the Druze community of
northern Israel,4 and, subsequently, other locations in
western Europe.5–9 To date, only 21 affected individuals
have been reported. Seizures, intellectual impairment,
and amelogenesis imperfecta were reported in all families,
and other clinical features varied among reports. The goal
of this project was to identify the gene and the mutation
responsible for KTS in the highly consanguineous Druze
community.
We have compiled 14 new KTS cases pertaining to five
families, all of which originate from the same small Druze
village in northern Israel. The index case (II-1 in family 1),
who was referred to us at the age of 13 months for the eval-
uation of seizures, was noted to have amelogenesis imper-
fecta. Individual II-1 and her parents and siblings, as well
as informative relatives of four other families with affected
children, were enrolled (Figure S1, available online). A
consanguineous liaison is evident for families 3, 4, and 5,
although the parents of the affected children in family 4
are not known to be related. Family 2, unrelated to families
3–5, is consanguineous too (Figure S1). The study was
approved by the institutional review board at Rambam
Health Care Campus, Haifa, and after signed informed
consent (self and parental), a blood sample was drawn
for DNA extraction from all available family members
(both affected and healthy individuals). All affected indi-1The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute
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geneticist, medical records were reviewed, and parents
were interviewed.
The clinical characteristics of 14 KTS-affected individuals
(seven males and seven females; ages 2–24 years) are de-
picted in Table 1. Born at term after normal gestation,
they all appeared normal at birth and had no apparent dys-
morphology.AlthoughallKTScasesultimatelydisplayedan
unequivocal phenotype heralded by seizures and ‘‘yellow
teeth,’’ they varied widely with regard to the severity of
the manifestations, even within the same nuclear family.
Family 4 has five affected children (V-4 to V-8) who all
had epileptic episodes that varied in age of onset, intensity,
frequency, and response to treatment. The firstborn child
(V-4), who died at the age of 2 years, was vegetative, failed
to thrive, and suffered from intractable convulsions and
microcephaly. Their second-born affected child (V-6) dis-
played impaired psychomotor development from the
first months of life and convulsive episodes, starting at
9 months of age, that were refractory to treatment. She
was nonverbal and nonambulant. It was noted that her
brother (V-5) lagged developmentally starting at 6 months
of age, and he is regularly maintained on anticonvulsants
(he has had a partial response). At 16.5 years of age, he is
awkwardly ambulant and nonverbal, performs mostly by
shouting and yelling, and is irritable and self-mutilating.
His 15-year-old sister (V-7) suffers from a convulsive
disorder that responds well to treatment, and, although
intellectually disabled, she manages to communicate
with her mother, utters a few words, and is ambulant.
The youngest sibling (V-8), currently 3.5 years old, has
a convulsive disorder that is only partially controlled,of Technology, 31096 Haifa, Israel; 2Institute of Human Genetics, Rambam
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Table 1. Clinical Characteristics of 14 Individuals Affected by KTS
Family 1 Family 2 Family 3 Family 4 Family 5
II-1 II-6 II-7 IV-1 IV-2 IV-4 V-1 V-3 V-4 V-5 V-6 V-7 V-8 V-12
Gender female female male female male male male female female male female female male male
Birth weight (grams) 3,500 3,500 3,500 3,250 3,250 3,500 2,500 2,400 2,300 3,140 2,800 3,500 3,800 3,500
Deliverya NVD NVD NVD NVD NVD NVD CS CS NVD NVD NVD NVD NVD NVD
Current age (years) 6 24 16 15.5 16.5 13.5 14.5 16.5 deceased
at age 2
16.5 19.5 15 3.5 4.5
Clinical characteristics
Age of first convulsion
(months)
13 12 9 12 6.5 42 9 9 birth 10 9 9 9 11
Seizure intensityb þ þþþ þþ þ þþþ þ þþþ þ þþþ þþ þþþ þ þ þþþ
Resistance to therapyc þ þþþ þþ þ þþþ þ þþþ þ þþþ þþ þþþ þ þ þþþ
Amelogenesis imperfecta yes yes yes yes yes yes yes yes N/A yes yes yes yes yes
Intellectual impairmentd þþþ þþþþ þþþ þþþ þþþ þþ þþþ þþ N/A þþþ þþþþ þþ þþþ þþþ
Speech no no no no no mumbling no mumbling N/A no no mumbling no no
Ambulant yes no yes yes yes yes no yes N/A yes no yes yes yes
Laboratory evaluation
EEGe N N/A N N/A abnormal abnormal N/A N/A N/A abnormal N/A N abnormal N
Brain MRIf abnormal abnormal abnormal N/A N N/A N/A N/A N/A abnormal N/A N/A N N
The following abbreviations were used: NVD, normal vaginal delivery; CS, cesarean section; N/A, not available; EEG, electroencephalogram; N, normal; and MRI, magnetic resonance imaging.
aAll individuals were born at term.
bSeizure intensity: þ, occasional; þþ, frequent; and þþþ, severe.
cTherapy resistance: þ, good response to treatment; þþ, control by treatment; and þþþ, refractory.
dIntellectual impairment: þ, mild; þþ, moderate; þþþ, severe; and þþþþ, profound.
eAn abnormal EEG revealed a pattern of slow, short epileptiform spikes and waves during light sleep and was normal thereafter.
fAn abnormal MRI revealed dilation of cerebellar sulci and third and lateral ventricles.
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and he is hyperactive, nonverbal, relatively ambulant, and
mentally disabled.
A wide interfamilial variability was again noted in
families 1, 2, and 3. Family 2 has three affected children
(IV-1, IV-2, and IV-4). The first affected boy (IV-2), who
was hypotonic and suckedpoorly as a neonate, experienced
intractable seizures beginning at 6.5 months of age. The
youngest boy (IV-4) was considered normal until, at the
age of three years, he experienced a convulsive episode.
Accordingly, IV-4 performs better than his older siblings.
Affected children from family 1 (II-1, II-6, and II-7) and
family 3 (V-1 and V-3) all presented with seizures at around
one year of age (between 9 and 13 months). The severity of
the epileptic events ranged from short convulsive episodes
that resolved under antiepileptic treatment (such as with
individuals II-1 and V-3) to generalized convulsions
partially controlled by anticonvulsants (II-7) to frequent
convulsive episodes resistant to therapy (II-6 and V-1).
Intellectual disability was noted to correlate with the
severity of the epileptic events. The phenotype displayed
by our KTS cases is consistent but variable. All cases dis-
played amelogenesis imperfecta, seizures, severe develop-
mental delay, and lack of speech. The magnitude of the
intellectual disability, although severe to profound, is still
directly related to the severity of the convulsive disorder
as manifested by age of onset and response to treatment.
Affected individuals lost their gross motor skills in either
early or late adolescence because they became spastic. The
most afflicted individualswerebedriddenearly in life.Meta-
bolicworkupwasnegative as a rule. Electroencephalograms
(EEGs) undertaken shortly after a convulsive episode were
interpreted, in most cases, as normal. Magnetic resonance
images (MRIs) were available for seven individuals. In four
of these individuals, dilatation of cerebellar sulci and third
and lateral ventricles was evident and should probably be
regarded as a correlate of cerebral atrophy.
With this in mind, the term ‘‘dementia’’ previously used
for defining a major characteristic of KTS is not valid for
the cases described here. KTS-affected children have global
developmental delay that is cortical in nature (intellectual
disability, spasticity, and seizures), and the progressive
nature of their neurological decline might be attributed
to, among other things, the intractability of their seizures
and, as such, epileptic encephalopathy.
Homozygosity mapping was carried out with the
assumptions that the disease follows a recessive model
and that a single responsible allele is shared by all affected
individuals. First, genomic DNA from ten affected individ-
uals, one healthy sibling, and one obligate carrier parent
was genotyped with the Illumina 6000 SNP array (BioRap
Technologies at the Rappaport Institute); thereafter, five
affected individuals were genotyped with the Affimetrix
GeneChip Human Mapping 250K Nsp microarray (Biolog-
ical Services Unit at the Weizmann Institute). Homozy-
gosity-by-descent analysis was carried out manually and
explored identical homozygous intervals in all affected
individuals. Candidate homozygous loci were genotyped710 The American Journal of Human Genetics 90, 708–714, April 6, 2with microsatellite markers derived from Marshfield
maps or with markers designed by us (our markers were
based on the Tandem Repeats Finder program and the
UCSC Human Genome Database). Haplotypes of family
members were manually constructed and analyzed with
SUPERLINK online. In the 6000 SNP array, the analysis
identified a candidate segment, in chromosomal region
16p13.3, spanning 2,670,304 bp between rs2075852
and rs1012259; only one homozygous SNP (rs85930)
shared homozygosity in all ten affected individuals,
whereas the healthy mother and sibling were heterozy-
gous. Evaluating this interval in the 250K SNP array,
we identified a homozygous segment spanning only
873,963 bp between rs11865087 and rs3760030; this
segment was shared by four of the five genotyped individ-
uals. The fifth affected individual was clinically reevaluated
and excluded from the research as a non-KTS case (data
not shown). We developed and genotyped the following
three microsatellite markers in this interval: GT32 at
chr16: 4,533,109–4,533,282 (marker 1); TG19 at chr16:
4,854,835–4,855,072 (marker 2); and GT31 at chr16:
5,105,840–5,106,041 (marker 3). We depict haplotypes in
Figure 1 to show the segregation of markers and SNPs in
affected individuals and healthy family members; there
are three affected and seven healthy individuals in family
1, three affected and two healthy individuals in family 2,
and six affected and eight healthy individuals in families
3–5 (Figure 1A). Individual V-4 (family 4), who died at
2 years of age, and individual V-8 (family 4), who has not
yet been diagnosed with KTS at this stage, were excluded
from the analysis. All affected individuals shared the
same homozygous haplotype for markers 2 and 3, and
a 586,513 bp segment between microsatellite marker 1
(chr16: 4,533,109) and rs3760030 (chr16: 5,119,872) was
defined as the linkage locus for KTS (Figure 1A). Under
a recessive model of full penetrance, the LOD score for
linkage of this region to KTS was 6.4.
Chromosomal region 16p13.3 harbors 17 genes. We
performed Sanger sequencing of coding regions and flank-
ing intron-exon boundaries on genomic DNA from one
affected individual (II-1 in family 1) by using the primers
that we designed. The genomic sequences were retrieved
from the UCSC Genome Browser (GRCh37/hg19 assembly
[Feb. 2009]). In the first ten genes, no potentially
damaging variants were found. In contrast, sequencing
of theDrosophila rogdi homolog, ROGDI (FLJ22386) (RefSeq
accession number NM_024589.1), yielded a homozygous
nonsensemutation (c.469C>T in exon 7) causing a prema-
ture stop codon, p.Arg157* (Figure 1B). This nonsense
mutation cosegregated with KTS in all five families; all
affected individuals were homozygous for the mutation,
all parents were heterozygous, and unaffected siblings
were either heterozygous or homozygous for the wild-
type allele. Of 100 unaffected adults from the same Druze
community, ten were heterozygous carriers of the muta-
tion; none were homozygous for the mutation. The muta-
tion was not observed in 100 Druze individuals from other012
Figure 1. Families 1–5 Haplotypes and the c.469C>T Mutation in Exon 7 of ROGDI
(A) Disease-associated haplotypes are shown in boxes. Markers 1 and rs3760030 define the minimal homozygosity locus associated with
the disease (allele 0: not genotyped). The numbers flanking the genotyped markers indicate the distance from 16pter (GRCh37/hg19
assembly).
(B) The ROGDI c.469C>T (p.Arg157*) mutation in genomic DNA of a KTS-affected individual compared to a control.
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Figure 2. Subcellular Localization of ROGDI in Transfected HEK 293 Cells and Blood Mononuclear Cells
(A–F) The immunostaining of ROGDI-transfected HEK 293 cells was performedwith a ROGDI polyclonal antibody incubated in the pres-
ence of a permeabilizing reagent (0.2% saponin). ROGDI labeling (A) was revealed with an Alexa Fluor-488 goat anti-rabbit secondary
antibody (green). Nuclei (B) were stained with DAPI (blue). The merged picture (C) shows the ROGDI-antibody staining (green) together
with nuclei staining (blue). As a control, the same experiment was performed with the secondary antibody in the absence of ROGDI
antibody (D, E, and F).
(G–R) The same ROGDI antibody was used for immunolocalization of native ROGDI in blood mononuclear cells (green signal in G, K,
and O). Colabeling was performed with a LAMIN A monoclonal antibody (red signal in H, L, and P). Nuclei (I, M, and Q) were stained
with DAPI (blue). The partial colocalization of ROGDI with LAMIN A is shown in (J), (N), and (R). Cells were observed by confocal
microscopy. Three cell sections from the middle to the top of cells are shown (G–J, K–N, and O–R, respectively). White scale bars repre-
sent 10mm.parts of Israel. Primer sequences and PCR conditions are
available upon request. The c.469C>T mutation was not
reported in the Exome Variant Server. No clinical links
were reported for SNPs in the gene.712 The American Journal of Human Genetics 90, 708–714, April 6, 2ROGDI (FLJ22386) is the human homolog of Drosophila
rogdi. The human gene encodes a 287 amino acid leucine
zipper protein of unknown function. Drosophila rogdi
encodes 343 and 268 amino acid isoforms. The stop at012
Figure 3. Immunostaining in Dermal Fibroblasts and Immuno-
blot Analysis from a KTS-Affected Individual and a Control
(A–F) Double immunostaining of LAMIN A and ROGDI in control
(A–C) and KTS (D–F) fibroblasts (II-1 in family 1). LAMIN A (green)
and ROGDI (red) were labeled with specific antibodies. Merged
images are shown in (C) and (F).
(G) Immunoblot shows absence of ROGDI in Epstein-Barr virus
(EBV)-transformed lymphoblasts from affected individuals
compared to controls. Lanes 1 and 2 show EBV-transformed
lymphoblasts of controls. Lanes 3 and 4 display EBV-transformed
lymphoblasts from affected individuals (II-1 in family 1; V-8 in
family 4). The upper bands indicate a molecular weight of
~32 kDa. Tubulin was used as a loading control.residue 157 of the human homolog corresponds to residue
156 of the shorter isoform and residue 231 of the longer
isoform in Drosophila. The most conserved domain of the
protein is the C terminus (residues 253–281 of the human
protein), shared by the human protein and bothDrosophila
isoforms and truncated by the stop mutation in the KTS-
affected families. Meta-analysis of genome-wide expres-
sion studies indicates that in both humans and mice,
ROGDI is expressed more in the hippocampus than in
other tissues.10 Our RT-PCR analysis indicates that ROGDI
is widely expressed and has higher levels in the adult brain,
spinal cord, peripheral blood, heart, and bone marrow but
lower (and still detectable) levels in many other tissues,
including the fetal brain (Figure S2).
Examination of the primary sequence of ROGDI does not
provide any clues about the subcellular localization of the
protein. To address this issue, we generated an expression
plasmid encoding wild-type ROGDI (pROGDI) after ampli-
fication of the full-length ROGDI cDNA by PCR with cDNA
from an adult human brain as a template (Clontech).
Cellular localization of ROGDI was thereafter evaluated
in three experiments. Human embryonic kidney (HEK)
293 cells were transfected with pROGDI and were exam-
ined by indirect immunofluorescence micoroscopy with
a rabbit anti-ROGDI polyclonal antibody (1 mg/ml rabbit
anti-ROGDI polyclonal antibody, Protein Tech Group,The AmChicago, IL, USA; Catalog No. 17047-1-AP) generated
against the entire protein and a 1:1,000 dilution of
secondary Alexa Fluor-488 (green) goat anti-rabbit anti-
body (Molecular Probes); the HEK 293 cells revealed
a strong nuclear labeling of multiple bright spots and virtu-
ally no cytoplasmic staining (Figures 2A–2F). Blood mono-
nuclear cells—treated with the same antibodies and
a 1:1,000 dilution of a mouse monoclonal LAMIN A
antibody (Abcam, Cambridge, UK) and conjugated with
a secondary Alexa Fluor-594 (red) goat anti-mouse anti-
body (Molecular Probes)—were counterstained with DAPI
and examined by confocal microscopy (Nikon D-Eclipse
C1 with EZ-C1 3.91 software) (Figures 2G–2R). Native
ROGDI colocalized with the nuclear envelope marker
LAMIN A (Figures 2J, 2N, and 2R), suggesting again that
ROGDI might belong to the nuclear envelope. The same
procedure was undertaken for the labeling of dermal fibro-
blasts cultured from individual II-1 and the control, except
that in this case, the ROGDI and LAMIN A antibodies
were conjugated with secondary Alexa Fluor-594 (red)
and Alexa Fluor-488 (green) antibodies (Molecular Probes),
respectively. As shown in Figures 3A–3C, this experiment
revealed that in dermal fibroblasts, ROGDI localizes to
the nucleus, and a strong labeling of the nuclear envelope
is associated with faint spots within the nucleus. Most
importantly, ROGDI was not detected in the fibroblasts
from affected individual II-1 (Figures 2D–3F). Consistent
with these data, the protein was also not detected by
immunoblotting (Figure 3G). These latter results confirm
the specificity of the labeling obtained with the ROGDI
antibody used in these experiments and are consistent
with the loss-of-function mutation (p.Arg157*) identified
in individuals with KTS.
ROGDI emerges as new player in neurogenesis. The
expression pattern of the gene, showing strong expression
in the adult brain and spinal cord, is in line with the
disease characteristics relevant to cortical dysfunction
and spasticity. However, its detectable expression in
many other sites that do not seem to be affected by the
disease raises the question of its physiological role in these
tissues. ROGDI (FLJ22386) has been reported to interact
with a protein called disrupted in schizophrenia 1 (DISC1)
(MIM 605210) in yeast two-hybrid screens.11 DISC1 is
deemed necessary for neuronal proliferation, the migra-
tion of cortical interneurons, and their proper differentia-
tion in the cerebral cortex.12 A plausible interaction
between ROGDI and DISC1, if confirmed by a proper
experimental set such as coimmunoprecipitation studies
in native cells, could offer a clue regarding the role of
ROGDI in the pathophysiology of KTS.
In summary, 14 KTS-affected individuals from a consan-
guineous Druze community share homozygosity for
a nonsense mutation in the human homolog of Drosophila
rogdi, which encodes a leucine zipper protein of unknown
function. The nonsense mutation would truncate a
highly conserved C-terminal domain. Mammalian ROGDI
is highly expressed in the hippocampus, and theerican Journal of Human Genetics 90, 708–714, April 6, 2012 713
corresponding protein localizes to the nuclear envelope.
Age of onset and the severity of the degenerative KTS
phenotype vary considerably among individuals who are
homozygous for the same disease allele and who are
from the same small community.
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